𝘽𝘼𝘾𝙆𝙍𝙂𝙍𝙊𝙐𝙉𝘿
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and commercializing products to address needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from sexually transmitted infections (STIs).
The Company's product, Phexxi vaginal gel, is an on-demand prescription contraceptive gel for women. Its pipeline product candidate, EVO100 vaginal gel, is evaluated for the prevention of chlamydia trachomatis infection and Neisseria gonorrhoeae in women. The Company also focuses on the development of EVO200 vaginal gel, its candidate for the reduction of recurrent bacterial vaginosis (BV).Its subsidiaries include Evofem Biosciences Operations Inc, Evofem Inc and Evofem Ltd (Source: Refinitiv)
𝙁𝙐𝙉𝘿𝘼𝙈𝙀𝙉𝙏𝘼𝙇𝙎
Evofem is my new $ASXC with Upside Potential even bigger than TRXC at that time. What is absolutely mind-boggling is the revenue growth, see below.
🔹️ Market Cap of $146M
🔹️ Revenue of 0.45M in FYO … 20.93 in FY1 … 75.05 in FY2 … and 158.41M in FY3 (!!!)
🔹️ Revenue growth of c.4600% then slowing down to 260% and 111%!
🔹️ Price to Sales of 363 in FYO, 7 in FY1, 1.95 in FY2 and 0.92 in FY3 (!!)
🔹️ Short Interest at 19.1% (just went down from 24%)
🔹️ Debt to Capital at 120.89%
🔹️ Cash of 45M
The company employs 147 people and is HQed in San Diego.
The biggest Institutional Investors are: Heights Capital Management at 6.65%, INVESCO at 6.16%, Blackrock at 3.46%, Vanguard at 2.77%.
𝙍𝙀𝘾𝙀𝙉𝙏 𝘿𝙀𝙑𝙀𝙇𝙊𝙋𝙈𝙀𝙉𝙏𝙎
🔹️ CEO Saundra L. Pelletier Purchases 50,000 shares (13.07.2021).
🔹️ Caas Capital Management Makes New Investment in Evofem (12.07.2021)
🔹️ Blackrock Increases Stock Position in Evofem (06.07.2021)
🔹️ Insider Buying: Director Acquires 10,000 Shares of Stock (22.06.2021)
🔹️ INPX incurs $12.5M Net Loss in First Quarter (25.05.2021)
🔹️ 73% MONTH-OVER-MONTH AVG. PHEXXI SALES GROWTH IN Q1’21 (Prez from 08.06.2021)
🔹️411.4M Video Views of its campaign with 12X increase in organic search traffic (Prez from 08.06.2021)
🔹️$1.5B – $2.4B U.S. Contraceptive Commercial Opportunity (Prez from 08.06.2021)
𝘾𝙊𝙉𝘾𝙇𝙐𝙎𝙄𝙊𝙉
Evofem Biosciences is a business that I have been watching for over a month and waited to take as big position as possible without exploding the risk. As you can see in recent developments, a lot of insiders, including the CEO, have been buying shares. I have seen a strong support at todays levels and short interest dropping from 24% to 19%, which is a lot on a day. We have a very strong backing from Institutional Investors.
What I love most is that the product is already commercialized, predicted to bring 150M in FY3, which will be more that its current market cap and the Upside of 580%. I do believe that with this rate of growth, we will hit 1B valuation, perhaps even this year. Marketing campaign has been a great success and I have 1st hand feedback from one of the Copiers that the product and the company is excellent. Having analysed the Investors Presentation from LD Micro Invitational XI Conference on 08.06.2021 – I really like what the CEO presented.
This one – to the Moon!
MJ
PS. All my investments and portfolio are public. To join eToro please follow the link: https://bit.ly/3i7Yo3C
My Public Profile: https://www.etoro.com/people/mj_lux
Please note that CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.